Sargramostim Use in COVID-19 to Recover Patient Health

NCT ID: NCT04707664

Last Updated: 2023-02-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 600 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-27
• Study Completion Date: 2022-01-31

Brief Summary

The purpose of this research is to understand if the study drug, also called sargramostim or Leukine®, can help prevent the worsening of COVID-19 when the study drug is inhaled. This study will also help researchers understand if inhaled sargramostim can help prevent visits to the emergency room or hospitalization, or death.

Detailed Description

This Phase 2b, multicenter, placebo-controlled, double-blind study will randomize approximately 500 adult patients who are symptomatic with mild or moderate COVID-19 (as defined in the FDA Guidance Document: Covid-19: Developing Drugs and Biological Products for Treatment or Prevention, May 2020) who are at high risk for progression to more severe disease. Patients will be randomized in a 1:1 ratio to inhaled sargramostim plus standard of care (SOC) or placebo plus SOC. Enrollment of patients who have completed a COVID-19 vaccination regimen or participated in a COVID-19 vaccine clinical trial will be capped at approximately 100 patients. All patients will be randomized to receive either 250 mcg of sargramostim or equivalent volume of placebo diluent. Treatment will be administered once daily for 5 days delivered via a vibrating mesh nebulizer. Patients will be followed for up to 60 days after start of treatment.

Sargramostim (Leukine) is a formulation of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), which is a critical cytokine for healthy pulmonary function. Detailed studies have shown that GM-CSF is necessary for alveolar macrophage (AM) maturation and maintenance. Although GM-CSF was discovered as a myelopoietic growth factor, it has diverse additional effects that both promote differentiation of myeloid precursors into neutrophils, monocytes, and dendritic cells and control function of mature myeloid cells. GM-CSF is also known to reverse immunoparalysis seen in sepsis, resulting in beneficial outcomes. In addition, GM-CSF prevents bacteremia in post influenza bacterial pneumonia through locally mediated improved lung antibacterial resistance and increased reactive oxygen species production by AMs. Pulmonary delivery of this GM-CSF has potential to reduce morbidity and mortality due to viral pneumonias, potentially including COVID-19.

Conditions

Covid19; SARS-CoV Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Sargramostim Arm

Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19

Group Type: EXPERIMENTAL

Sargramostim

Intervention Type: DRUG

All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days.

Placebo Arm

Day 1 - 5: Placebo treatment in addition to standard of care for COVID-19

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.

Interventions

Sargramostim

All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days.

Intervention Type: DRUG

Placebo

All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.

Intervention Type: DRUG

Other Intervention Names

Leukine; GM-CSF

Eligibility Criteria

Inclusion Criteria

1. Patients with a positive laboratory diagnosis of SARS-CoV-2 infection by an antigen or a molecular test ≤5 days prior to randomization. The test should have been authorized by the relevant regulatory authority.

2. Have one or more of the following mild or moderate COVID-19 symptoms for ≤5 days prior to randomization:

1. Fever or chills

2. New onset or worsening cough

3. Sore throat

4. Malaise or fatigue

5. Headache

6. Muscle pain (myalgias) or body aches

7. Gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea)

8. New onset or worsening shortness of breath or difficulty breathing

9. Nasal congestion or runny nose

10. New loss of taste (ageusia) and/or smell (anosmia). Note: any of these symptoms (ageusia, anosmia) alone or in combination cannot be used as the SOLE qualifying symptoms for enrollment.

3. At higher risk for progression to more severe COVID-19

1. Age ≥ 60 years

2. Age 18-59 years with a clinically stable medical history of at least 1 or more of the following conditions that could lead to severe COVID-19:

• Chronic respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis
• Obesity with BMI ≥ 30 kg/m2
• Cardiovascular disease
• Sickle cell disease or thalassemia
• Diabetes mellitus being managed with concomitant medications
• Hypertension being managed with concomitant medications
• Chronic kidney disease

4. Oxygen saturation by pulse oximeter > 93% on room air. Note: at altitudes of >4000 feet above sea level, oxygen saturation by pulse oximeter > 91% on room air is permitted

5. Negative pregnancy test (if woman of childbearing potential)

6. Females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods from screening to Day 28

7. The patient (or legally authorized decision maker) must give informed consent

Exclusion Criteria

1. Hospitalized patients

2. Patients who have received or are receiving other treatments that are not approved/authorized by the relevant regulatory authority for the treatment of patients with mild or moderate COVID-19 in an outpatient setting

3. Patients enrolled in interventional clinical trials for other experimental therapies

4. Patients on chronic oxygen supplementation due to cardiopulmonary or other conditions

5. Patients with unstable comorbid conditions (e.g., decompensated congestive heart failure, COPD with exacerbation, current angina pectoris, uncontrolled diabetes mellitus, uncontrolled hypertension, uncontrolled asthma)

6. Patients with severe pulmonary comorbid conditions, including systemic steroid-dependent asthma, systemic steroid-dependent COPD, oxygen-dependent COPD, lung transplant, or cystic fibrosis

7. Patients who have received highly immunosuppressive therapy (to include systemic corticosteroids) or anti-cancer combination chemotherapy within 24 hours prior to first dose of study drug

8. Patients with known or suspected intolerance or hypersensitivity to sargramostim, or any component of the product

9. Patients who have previously experienced severe and unexplained side effects during aerosol delivery of any kind of medical product

10. Pregnant or breastfeeding females

11. Patients who, in the opinion of the Investigator, will not be able to comply with all the study procedures and visits as outlined in the schedule of events, including follow-up

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

United States Department of Defense

FED

Sponsor Role: collaborator

Partner Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Fiona Garner, PhD

Role: STUDY_DIRECTOR

Partner Therapeutics, Inc.

Locations

West Valley Research Clinic, LLC

Phoenix, Arizona, United States

Applied Research Center of Arkansas

Little Rock, Arkansas, United States

Hope Clinical Research

Canoga Park, California, United States

Benchmark Research

Colton, California, United States

Synergy Healthcare

Bradenton, Florida, United States

Invesclinic US, LLC.

Fort Lauderdale, Florida, United States

Indago Research & Health Center, Inc. (Subject Visits Only)

Hialeah, Florida, United States

Encore Medical Research

Hollywood, Florida, United States

IMIC Inc.

Palmetto Bay, Florida, United States

Encore Medical Research of Weston

Weston, Florida, United States

Gwinnett Research Institute, LLC

Buford, Georgia, United States

Paramount Research Solutions

College Park, Georgia, United States

TidalHealth Peninsula Regional, Inc.

Salisbury, Maryland, United States

Revive Research Institute, Inc.

Farmington Hills, Michigan, United States

Revival Research Institute, LLC.

Sterling Heights, Michigan, United States

Olive Branch Family Medical Center

Olive Branch, Mississippi, United States

Great Plains Health

North Platte, Nebraska, United States

Excel Clinical Research

Las Vegas, Nevada, United States

Richmond University Medical Center

Staten Island, New York, United States

Monroe Biomedical Research

Monroe, North Carolina, United States

Hometown Urgent Care and Research

Cincinnati, Ohio, United States

Hometown Urgent Care and Research

Columbus, Ohio, United States

Urgent Care Specialists, LLC DBA Hometown Urgent Care and Research

Dayton, Ohio, United States

TruCare Internal Medicine and Infectious Disease

DuBois, Pennsylvania, United States

Urgent Care Clinical Trials @ AFC Urgent Care - Easley

Easley, South Carolina, United States

University Diabetes & Endocrine Consultants

Chattanooga, Tennessee, United States

UCCT @ City Doc Urgent Care-McKinney

Dallas, Texas, United States

Invesclinic US LLC

Edinburg, Texas, United States

Dorrington Medical Associates

Houston, Texas, United States

Encore Imaging & Medical Research

Houston, Texas, United States

SMS Clinical Research, LLC

Mesquite, Texas, United States

Novotrial Research Group

Pearland, Texas, United States

Sun Research Institute

San Antonio, Texas, United States

University of Utah Health

Salt Lake City, Utah, United States

Centro de Investigaciones Medicas Mar del Plata

Mar del Plata, Buenos Aires, Argentina

Instituto Medico de la Fundacion Estudios Clinicos

Rosario, Santa Fe Province, Argentina

Sanatorio Santa Barbara

Buenos Aires, , Argentina

Countries

United States; Argentina

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

PTX-001-003

Identifier Type: -

Identifier Source: org_study_id